Invivyd, INC

Invivyd announces positive topline results from its LIBERTY Phase 3 study for VYD2311, demonstrating superior safety and tolerability compared to an mRNA COVID-19 vaccine and paving the way for regulatory submission.

Invivyd announced the appointment of Marc Elia as CEO and provided an update on its VYD2311 clinical studies, with results expected soon.

Invivyd announced second quarter 2026 financial results, highlighting a 21% increase in PEMGARDA net product revenue to $14.3 million and progress in key clinical trials for VYD2311.

Invivyd, Inc. received a deficiency letter from Nasdaq for failing to meet the minimum $1.00 bid price requirement for its common stock.

Invivyd, Inc. announced it has received a twelve-month advanced notice of termination for the Emergency Use Authorization (EUA) of its COVID-19 monoclonal antibody, PEMGARDA, from the U.S. FDA, effective June 29, 2027.

Invivyd, Inc. announced the results of its Annual Meeting of Stockholders held on May 19, 2026, including the election of directors and ratification of PricewaterhouseCoopers LLP as its independent auditor.

Invivyd, Inc. filed its Q1 2026 10-Q report, detailing a net loss of $41.4 million and continued investment in its VYD2311 COVID-19 program.

Invivyd, a biopharmaceutical company, reported significantly reduced net losses and increased product revenue in Q3 2025, while advancing its VYD2311 COVID-19 prevention program with positive FDA feedback.

Invivyd, Inc. reported a significantly reduced net loss in the second quarter of 2025, driven by increased PEMGARDA sales, while advancing its next-generation COVID-19 antibody, VYD2311, towards potential BLA approval.

Invivyd, Inc. reports its first quarter 2025 financial results, including $11.3 million in product revenue, but expresses substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows.

Invivyd, Inc. reported its third quarter 2024 financial results, highlighting revenue from PEMGARDA sales and progress in clinical development of its next-generation antibody candidate.

Invivyd, Inc. reports its first product revenue following emergency use authorization for PEMGARDA, while also disclosing substantial doubt about its ability to continue as a going concern.

Invivyd, Inc. reports increased PEMGARDA sales and significant clinical progress for VYD2311 in 2025, yet faces substantial doubt about its ability to continue as a going concern due to recurring losses.

Invivyd's 10-K filing highlights the company's focus on commercializing PEMGARDA and advancing VYD2311, while navigating financial uncertainties and regulatory landscapes.

Invivyd, Inc.'s 10-K filing outlines the company's common stock details, regulatory environment, and recent emergency use authorization for PEMGARDA.

Ian Sheffield, a Director of Invivyd, Inc., received 100,000 shares of common stock on August 31, 2026.

Marc Elia, Chief Executive Officer and a Director of Invivyd, Inc., received 10,700,000 shares of common stock on August 30, 2026.

Timothy Edward Lee, Chief Commercial Officer of Invivyd, Inc., sold 40,780 shares of common stock on August 15, 2026.

Julie Green, Chief Human Resources Officer of Invivyd, Inc., sold 40,780 shares of common stock on August 15, 2026.

William E. Duke, Chief Financial Officer of Invivyd, Inc., sold 40,780 shares of common stock on August 15, 2026.

Jill Andersen, Chief Legal Officer, Secretary of Invivyd, Inc., sold 67,962 shares of common stock on August 15, 2026.

Invivyd, Inc. has issued its proxy statement detailing the upcoming 2026 Annual Meeting of Stockholders, scheduled for May 19, 2026, to elect directors and ratify auditor appointments.

Invivyd, Inc. announces its 2025 Annual Meeting of Stockholders to be held on May 20, 2025, and provides details on how stockholders can vote on key proposals.

Invivyd, Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on May 20, 2025, featuring proposals for director elections and ratification of the company's independent accounting firm.

Invivyd, Inc. announces its 2024 Annual Meeting of Stockholders to be held virtually on May 21, 2024, to elect directors and ratify the appointment of PricewaterhouseCoopers LLP as the company's independent accounting firm.

Adimab, LLC has reported a decrease in its beneficial ownership of Invivyd, Inc. common stock to 7.3% following recent open market sales.

Adimab, LLC has reduced its beneficial ownership in Invivyd, Inc. to 8.8% after selling over 1.2 million shares in open market transactions.

Mithril Capital Management's beneficial ownership in INVIVYD, INC. decreased to 4.8% due to dilution from the issuer's recent share sales.

Polaris Partners and affiliated entities report a decrease in their aggregate beneficial ownership of INVIVYD, INC. common stock to 3.0% following the issuer's recent share sales.

M28 Capital Management LP and Marc Elia have filed an exit amendment to their Schedule 13D for Invivyd, Inc., indicating their beneficial ownership has fallen below 5% due to an increase in outstanding shares.

RA Capital Management and its affiliates report a 7% beneficial ownership stake in Invivyd, Inc. through pre-funded warrants.

Maverick Capital, Ltd. and its affiliates have filed an amended Schedule 13G, reporting a 6.7% beneficial ownership stake in Invivyd, Inc. as of December 31, 2025.

Soleus Capital Management and affiliated entities report a combined 2.8% passive beneficial ownership in Invivyd, Inc. common stock.

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have disclosed a 7.9% beneficial ownership stake in INVIVYD, INC., totaling 21,785,166 shares.

Point72 Asset Management, L.P. and affiliates have disclosed a 9.7% beneficial ownership stake in Invivyd, Inc., totaling over 20 million shares.

Janus Henderson Group plc and its affiliates have reported a 12.1% beneficial ownership stake in INVIVYD, INC. common stock, held for investment purposes.